Completed study to assess the effects of nicotinamide riboside (NR) and pterostilbene (PT) on UV-induced swelling, immunosuppression, and markers of DNA damage in mice; study will be published in 2021 or 2022.
Completed human clinical trial to study the effects of Basis on liver fat accumulation in healthy adults with fatty liver; results will be announced in 2021 and published by 2022.
Published in BMC Nephrology, the Phase I human clinical trial, conducted in partnership with Massachusetts General Hospital, enabled the FDA approval of an Investigational New Drug application for Basis and the AKI Phase II trial.
Acute Kidney Injury (AKI) Phase II
Initiated at Mayo Clinic, the human clinical trial will evaluate the efficacy of Basis for the prevention of AKI in patients that have undergone a cardiac surgery; primary study completion date October 2023.